TABLE 1.
Associations of Infants’ Clinical Characteristics at Sample Collection and Presence of Postnatal CMV Infection and Antiviral Treatment
| CMVPNT vs. NEG | CMVPT vs. NEG | ||||||
|---|---|---|---|---|---|---|---|
| NEG (n = 50) | CMVPNT (n = 26) | CMVPT (n = 27) | OR (95% CI) | P | OR (95% CI) | P | |
| Me (IQR) age at sample collection [days] | 42 (35–55) | 61.5 (54–72) | 57 (48–65) | 1.06 (1.03–1.1) | <0.001 | 1.04 (1.01–1.07) | 0.011 |
| viral load >100,000 copies/ml | |||||||
| Blood [n (%)] | 0 (0) | 0/3 (0) | 4/10 (40) | – | – | – | – |
| Urine [n (%)] | 0 (0) | 19/24 (79.2) | 16/25 (64) | – | – | - | - |
| Hepatosplenomegaly [n (%)] | 16/49 (32.7) | 20 (76.9) | 16/26 (61.5) | 6.87 (2.31–20.45) | <0.001 | 3.3 (1.23–8.88) | 0.018 |
| Jaundice [n (%)] | 12/49 (24,5) | 2 (7,7) | 11/26 (44) | 0.26 (0.05–1.25) | 0.092 | 2.42 (0.87–6.74) | 0.09 |
| Me (IQR; n) AST [μkat/l] | 1.67 (0.65–3.62; 26) | 0.82 (0.51–1.12; 12) | 1.26 (0.96–3.25; 24) | 0.65 (0.35–1.19) | 0.162 | 1.07 (0.86–1.33) | 0.535 |
| Me (IQR; n) ALT [μkat/l] | 0.35 (0.27–0.99; 25) | 0.4 (0.29–0.68; 12) | 0.51 (0.36–0.99; 24) | 0.72 (0.26–1.99) | 0.528 | 1.2 (0.76–1.88) | 0.435 |
| Me (IQR; n) γ–GT [μkat/l] | 1.8 (1.04–5.96; 23) | 1.65 (1.26–2.32; 9) | 2.62 (1.46–5.16; 22) | 0.8 (0.55–1.17) | 0.245 | 0.96 (0.78–1.19) | 0.712 |
| Me (IQR; n) direct bilirubin [μmol/l] | 39 (0–85; 19) | 0 (0–6; 9) | 62 (0.5–115.5; 16) | 0.95 (0.9–1) | 0.067 | 1 (0.99–1.01) | 0.716 |
| Me (IQR; n) total bilirubin [μmol/l] | 64.5 (25.5–114; 20) | 9 (6–32; 11) | 102.65 (10.5–143; 16) | 0.96 (0.93–1) | 0.03 | 1 (0.99–1.01) | 0.654 |
| Me (IQR; n) platelet count [×109/l] | 225 (114–294; 33) | 153.5 (126.5–244; 24) | 80 (66–159; 23) | 1 (1–1) | 0.977 | 0.98 (0.98–0.99) | 0.001 |
| Me (IQR; n) leukocyte count [×109/l] | 15.9 (11.3–20.6; 34) | 10.7 (8.7–11.9; 23) | 12.3 (9.3–17; 23) | 0.8 (0.7–0.92) | 0.001 | 0.9 (0.81–0.99) | 0.038 |
| Me (IQR; n) neutrophils count [×109/l] | 5.95 (3.85–7.95; 32) | 1.75 (1.1–3.95; 16) | 4.2 (2.8–7.1; 21) | 0.58 (0.41–0.82) | 0.002 | 0.91 (0.8–1.04) | 0.187 |
| Me (IQR; n) CRP [mg/l] | 8 (5–22; 35) | 8 (5–19; 18) | 19 (7–44; 25) | 0.98 (0.95–1.02) | 0.331 | 1.02 (1–1.04) | 0.081 |
| Me (IQR) minimal FiO2 | 0.3 (0.23–0.45) | 0.25 (0.21–0.3) | 0.4 (0.35–0.55) | 0.02 (0–1.1) | 0.056 | 8.3 (0.93–74.22) | 0.058 |
| Me (IQR) maximal FiO2 | 0.35 (0.25–0.55) | 0.27 (0.22–0.4) | 0.41 (0.35–0.6) | 0.02 (0–0.67) | 0.03 | 4.04 (0.59–27.84) | 0.157 |
CI, confidence interval; CMVPNT, CMV positive without antiviral treatment group; CMVPT, CMV positive on antiviral therapy group; IQR, interquartile range; Me, median; n, number of subjects; NEG, CMV negative group (control group); OR, odds ratio.